Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis.

[1]  International System for Human Cytogenetic Nomenclature , 2020, Definitions.

[2]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[3]  R. Bristow,et al.  Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet–FISH , 2005, Breast Cancer Research and Treatment.

[4]  M. Lacroix,et al.  Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.

[5]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[6]  J. Trent,et al.  Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants , 1987, Molecular and cellular biology.

[7]  T. Hsu,et al.  A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. , 1979, Journal of the National Cancer Institute.

[8]  M. Olivé,et al.  Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization , 1978, In Vitro.

[9]  A. Chambers,et al.  A New Model for Lymphatic Metastasis: Development of a Variant of the MDA-MB-468 Human Breast Cancer Cell Line that Aggressively Metastasizes to Lymph Nodes , 2005, Clinical and Experimental Metastasis.